Find a John Waite - Essential - 1976 - 1986 first pressing or reissue. Complete your John Waite collection. Shop Vinyl and CDs. Rfhutil Download Windows. MASK OF SMILES. Download Lagu Radja Band Call Me.

Menustrip 3 0 2 Crackers. The present invention relates to a human beta-defensin inducing agent that comprises at least one fat or oil of an essential fatty acid triglyceride or a derivative thereof as the main active ingredient. It also relates to cosmetic, dermatological and pharmacological formulations comprising the at least. Patent WOA1 - Dermatological compositions comprising a fat or oil of an essential fatty acid triglyceride. Publication number WO A1 Publication type Application Application number PCT/GB2010/002043 Publication date Jun 3, 2011 Filing date Nov 9, 2010 Priority date Nov 27, 2009 Also published as,,, Publication number PCT/2010/2043, PCT/GB/10/002043, PCT/GB/10/02043, PCT/GB/2010/002043, PCT/GB/2010/02043, PCT/GB10/002043, PCT/GB10/02043, PCT/GB10002043, PCT/GB1002043, PCT/GB2010/002043, PCT/GB2010/02043, PCT/GB, PCT/GB201002043, WO 2011/064524 A1, WO A1, WO A1, WO-A1-, WO2011/064524A1, WO A1, WOA1 Inventors,, Applicant Export Citation,, (10), (2), (2), (25), (6) External Links.

The human beta-defensin inducing agent of any preceding claim, wherein the or each oil of an essential fatty acid triglyceride or derivative thereof comprises a triglyceride of cis 7, 10, 13-hexadecatrienoic acid, linoleic acid, a-linoleic acid, v-linoleic acid, stearidonic acid, eicosadienoic acid, dihomo-Y-linoleic acid, eicosatrienoic acid, eicosatetraenoic acid, arachidonic acid, eicosapentaenoic acid, docosadienoic acid, adrenic acid, docosapentaenoic acid, docosahexaenoic acid or tetracosapentaenoic acid or their corresponding acids. DERMATOLOGICAL COMPOSITIONS COMPRISING A FAT OR OIL OF AN ESSENTIAL FATTY ACID TRIGLYCERIDE The present invention relates to a human beta-defensin inducing agent that comprises at least one fat or oil of an essential fatty acid triglyceride or a derivative thereof as the main active ingredient. The present invention relates to cosmetic, dermatological and pharmacological formulations comprising the at least one fat or oil. The human skin is in permanent contact with various pathogenic micro-organisms but still typically remains free from signs of infection. This is due to the physical barrier of the skin and also to the synthesis of several antimicrobial agents.

These antimicrobial agents form a part of the innate immune system of the skin which is the first line of defence against microbial infection. Many peptides have been discovered that have antimicrobial activity. Antimicrobial peptides are small, cationic, amphiphilic peptides of 12 to 50 amino acids which have microbial activity against bacteria, fungi, protozoa and viruses. Mammalian defensins are one sub set of antimicrobial peptides which are subdivided into three main classes, namely alpha-defensins, beta-defensins and theta-defensins. Mammalian alpha- defensins are predominately found in neutrophils and in small intestinal Paneth cells whereas mammalian beta-defensins have been isolated from both leukocytes and epithelial cells: Beta-defensins are known to be expressed in the mucosa and in the epithelia cells of the skin, lungs, trachea, tongue, tonsils, saliva, kidneys and genitals. Six types of Beta-defensin have been currently isolated and their structures identified i.e.

Human beta-defensin-1 (hBD-1) to hBD-6 respectively. HBD-2 and hBD-3 can both be induced in the human body, hBD-2 in the skin, trachea and lungs and hBD-3 in the skin, trachea, tonsils and tongue. HBD-2 is synthesised and stored in lamellar bodies of keratinocytes within the spinous and granular layer of the skin and hBD-2 levels in the skin are normally very low. The hBD-2 is released during differentiation and after skin barrier disruption, for example in times of inflammation to protect the skin, wounds and burns. Examples of times of inflammation to protect the skin include during prolonged sun exposure, bacterial infection, skin diseases such as psoriasis and acne vulgaris lesions.

HBD-2 has been shown to have excellent antimicrobial activity against certain bacteria, namely Escherichia coli, Pseudomonas aeruginosa, which is a common cause of burn infections, and along with hBD-3 against Staphylococcus aureus, which is the most common single isolate in wounds in mammals with diabetes. HBD-2 has also been shown to have excellent antimicrobial activity against certain fungi, for example Candida albicans. The expression of human beta-defensins is known to be enhanced at cutaneous wound sites. Burn wounds are associated with high levels of circulating pro-inflammatory cytokines and immunosuppression, promoting systemic inflammatory response syndrome and sepsis. Beta-defensins, in particular hBD-2, have been identified at burn sites and are believed to participate in burn wound healing. As well as the above properties associated with the innate immune system hBD-2 has also been found to have chemotactic properties for immature dendritic cells, some types of T and B-lymphocytes, neutrophils and macrophages, and act as adjuvants which can enhance adaptive immunity.